The Oncology Bet Is Already Paying Off For Pfizer
We are experiencing some temporary issues. The market data on this page is currently delayed. Please bear with us as we address this and restore your personalized lists.
Amgen dismisses bone density concerns related to its new weight-loss drug
The company's stock slumped 7% on Tuesday after analysts at Cantor Fitzgerald said their review of early-stage data on Amgen's MariTide showed the drug had led to a drop in bone mineral density.